Table 1 Summary of prioritized drug candidates
Drug | Drug targets | Mechanism of action | Original indication | Approximate retail price |
|---|---|---|---|---|
Amiloride | ADCY10; AOC1; ASIC1; ASIC2; ASIC3; ASIC4; PKD2; PKD2L1; PLAT; PLAU; SCNN1A; SCNN1B; SCNN1D; SCNN1G; SLC9A1; SLC9A2; SLC9A3; TRPC7; TRPV2 | Sodium channel blocker | hypertension, congestive heart failure | $ |
Amisulpride | DRD3; HTR7 | Dopamine receptor antagonist | Psychosis, bipolar disorder, schizophrenia | N/A |
Amitriptyline | ADRA1A; ADRA1B; ADRA1D; ADRB1; ADRB2; ADRB3; CHRM1; CHRM4; CHRM5; CYP2C9; HRH1; HRH2; HRH4; HTR1B; HTR1D; HTR6; HTR7; KCNA1; KCND2; KCND3; KCNQ2; KCNQ3; NTRK1; NTRK2; OPRD1; OPRK1; OPRM1; ORM2; SIGMAR1; SLC6A2; SLC6A4 | Norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin–norepinephrine reuptake inhibitor (SNRI) | Depression | $ |
Bromocriptine | ADCY10; ADRA1A; ADRA1B; ADRA1D; ADRA2B; ADRA2C; DRD1; DRD3; DRD4; GH1; HTR1B; HTR1D; HTR2B; HTR6; HTR7; PRL; PRLR | Dopamine receptor agonist | Hyperprolactinemia, Parkinson's Disease, acromegaly | $$$$ |
Crizotinib | ALK; AXL; CYP2B6; CYP3A5; EPHA2; EPHA6; EPHB6; IRAK1; IRAK3; LTK; MAP3K2; MAP4K1; MAP4K2; MAP4K3; MAP4K5; MERTK; MET; MST1R; NTRK2; NTRK3; NUDT1; PLK4; ROS1; SLK; STK10; TEK; TIE1 | Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor | Non-small cell lung cancer (NSCLC) | $$$$$ |
Diltiazem | CACNA1C; CACNA1S; CACNA2D1; CACNG1; CYP3A5; CYP3A7; EDN1; HTR3A; KCNA5 | Calcium channel blocker | Hypertension, angina pectoris | $$$$ |
Fenofibrate | ABCD2; ABCD3; ABCD4; APOA1; APOB; APOC3; APOE; CCL2; CETP; CRAT; CRP; CYP2C8; CYP2C9; LPL; MMP25; NR1I2; PPARA; PPARD; PPARG; SERPINE1; SREBF2; VCAM1 | Peroxisome proliferator-activated receptor (PPAR) receptor agonist | Hypercholesterolemia, hypertriglyceridemia | $$$ |
Fluoxetine | ANO1; CHRNA2; CHRNA3; CHRNB4; CKS1B; CYP2C9; HTR2B; KCNH2; SLC6A4 | Selective serotonin reuptake inhibitor (SSRI) | Depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder | $$ |
Fluphenazine | ADCY10; AR; CALM1; CALM2; CALM3; CHRNA7; DRD1; HRH1; HTR1E; HTR6; HTR7 | Dopamine receptor antagonist | Schizophrenia | $$$$ |
Fluvastatin | APOA1; APOB; APOE; CYBA; CYP2C8; CYP2C9; F3; HMGCR; ICAM1; LDLR; RHOA; SELP; SERPINE1 | Hydroxymethylglutaryl-CoA reductase (HMGCR) inhibitor | Hypercholesterolemia, congenital heart defects | $$$$ |
Imipramine | ADRA1A; ADRA1B; ADRA1D; CHRM1; CHRM4; CHRM5; DRD1; FMO1; HRH1; HTR6; HTR7; KCND2; KCND3; KCNH1; KCNH2; ORM2; SLC22A3; SLC6A2; SLC6A3; SLC6A4 | Norepinephrine reuptake inhibitor, serotonin reuptake inhibitor | Depression, nocturnal enuresis | $$$$ |
Mirtazapine | ADRA1A; ADRA1B; ADRA1D; ADRA2B; ADRA2C; ADRB1; ADRB2; DRD1; DRD3; HRH1; HRH3; HTR2B; HTR3A; HTR7; OPRK1; SLC6A2; SLC6A3; SLC6A4 | Adrenergic receptor antagonist, serotonin receptor antagonist | Depression | $ |
Nicotine | AOX1; CHAT; CHRNA1; CHRNA10; CHRNA2; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNA9; CHRNB2; CHRNB3; CHRNB4; CHRND; CHRNE; CYP19A1; CYP2A6; CYP2B6; CYP2E1; CYP2U1; FMO1; FMO2; FMO3; FMO4; FMO5; FMO6P; FOS; INMT; PNMT; TBXAS1; TH; TRPA1; UGT1A4; UGT2B10; UGT2B11 | Acetylcholine receptor agonist | Smoking cessation | N/A |
Paclitaxel | ABCB1; BCL2; CYP2C8; KIF11; KIF1A; KIF1B; KIF1C; KIF5B; MAP2; MAP4; MAPT; NDC80; NR1I2; NUF2; TLR4; TUBB; TUBB1 | Tubulin polymerization inhibitor | Ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | $$$ |
Perphenazine | AOX1; CALM1; CALM2; CALM3; DRD1; HRH1; HTR6; HTR7 | Dopamine receptor antagonist | Schizophrenia, nausea, vomiting | $$ |
Pravastatin | ABCC2; APOB; CCL2; CETP; CRP; HMGCR; LCAT; SELP; SLCO1B1 | Hydroxymethylglutaryl-CoA reductase (HMGCR) inhibitor | Hypercholesterolemia, myocardial infarction, hyperlipidemia | $ |